15 results
8-K
ARCT
Arcturus Therapeutics Holdings Inc
8 May 24
Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress
4:05pm
-FLU), ARCT-032 (LUNAR-CF)), the qualification for commercial milestones under the CSL collaboration, the continuation and expected recruitment … in the Phase 3 pivotal study of ARCT-2303 candidate vaccine containing the Omicron XBB.1.5 variant, the ongoing recruitment in the ARCT-2138 (LUNAR-FLU
8-K
EX-99.1
ARCT
Arcturus Therapeutics Holdings Inc
8 May 24
Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress
4:05pm
to recruitment.
Both the geometric mean titer (GMT) ratio and seroresponse rate (SRR) difference of neutralizing antibodies against SARS-CoV-2 (Omicron BA.4 … . The recruitment of older adults is ongoing.
In April, the Company presented Phase 1 single ascending dose (SAD) studies for ARCT-810, an mRNA therapeutic
8-K
EX-99.1
ml3tv81vnxq5t9ge
9 May 23
Arcturus Therapeutics Announces First Quarter 2023 Financial Update and Pipeline Progress
4:11pm
10-K
47w6o84xn6o9
16 Mar 20
Annual report
11:09am
424B3
93h1uexi8s1d
12 Apr 19
Prospectus supplement
4:39pm
S-4/A
vyma61jdus grvpq
11 Apr 19
Registration of securities issued in business combination transactions (amended)
5:26pm
S-4
tihs86c8 2niwj4boub
15 Mar 19
Registration of securities issued in business combination transactions
9:35pm
- Prev
- 1
- Next